Cimzia (certolizumab pegol) / Astellas, UCB, Ferring - LARVOL DELTA

Drug-Induced Pancreatitis Across UC Therapeutics: A Real-World Pharmacovigilance Study (ACG 2026) - " FAERS was queried for reports of pancreatitis associated with UC treatments including immunomodulators (azathioprine, mercaptopurine, methotrexate, tacrolimus), 5-aminosalicylates (mesalamine, balsalazide, olsalazine, sulfasalazine), anti-TNF agents (adalimumab, infliximab, golimumab, certolizumab pegol), integrin inhibitors (vedolizumab, natalizumab), IL-12/23 inhibitors (ustekinumab, risankizumab, guselkumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod). 83,046 reports with 612 pancreatitis cases were analyzed. Significantly elevated risk was observed with azathioprine (ROR 4.38, 95% CI 3.56-5.38), mesalamine (ROR 2.32, 95% CI 1.87-2.89), and infliximab (ROR 1.47, 95% CI 1.21-1.80; all p< 0.0001). Reduced risk was identified with adalimumab (ROR 0.60, 95% CI 0.49-0.74), vedolizumab (ROR 0.69, 95% CI 0.51-0.93), and ustekinumab (ROR 0.13, 95% CI 0.02-0.94)."

Adverse events • Clinical • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pancreatitis • Ulcerative Colitis • IL12A • ROR1

Perioperative Safety Profile of IBD Medications: A Comparative Study of Real World Pharmacovigilance Data (ACG 2026) - "Golimumab showed elevated UC sepsis (1.88), whereas Adalimumab and Certolizumab showed lower CD sepsis (0.54, 0.27) and Adalimumab lower DVT and PE in both indications. Vedolizumab showed elevated UC DVT and PE (~1.5); natalizumab elevated CD PE (2.30); ustekinumab an isolated UC ileus signal (14.15)... Thiopurines and Methotrexate showed the most consistent signals across both indications: elevated ROR for sepsis (Azathioprine UC: ROR 2.03, CD: 1.85; Mercaptopurine UC: 2.64, CD: 2.04; Methotrexate UC: 1.57), DVT (Methotrexate UC 4.15, CD 2.33; Azathioprine CD 2.23, Mercaptopurine UC 2.29), and PE (Methotrexate UC 1.96; Azathioprine CD 1.84). Azathioprine UC also showed elevated anastomotic leak (7.15). Among anti-TNFs, infliximab showed elevated CD sepsis (2.12), DVT (1.90), and PE (1.82), as well as UC DVT (1.32)."

Adverse events • Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Septic Shock • Ulcerative Colitis

Abdominal Pain in Crohn's Disease: Tubo-Ovarian Abscess as a Complication of Enteric Leakage vs Entero-Adnexal Fistulization (ACG 2026) - "Case Description/ A 30-year-old woman with severe penetrating Crohnâs disease complicated by recurrent fistulization and bowel resections, who achieved remission with risankizumab and certolizumab, presented with worsening right-sided abdominal and flank pain. Figure: Coronal CT scan demonstrating tubo-ovarian abscess. Figure: Coronal MR enterography demonstrating tubo-ovarian abscess."

Crohn's disease • Gastroenterology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Nephrology • Pain

Herpes Zoster Infection as an Adverse Reaction to Treatments for Ulcerative Colitis: A Review of Reports to the FDA Adverse Events Reporting System (FAERS) (ACG 2026) - "Reports of ADRs of all FDA approved UC therapies including mesalamine, sulfasalazine, balsalazide, olsalazine, methotrexate, azathioprine, 6-mercaptopurine, infliximab, adalimumab, certolizumab, golimumab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, ozanimod, etrasimod, tofacitinib, and upadacitinib along with combination infliximab with methotrexate, infliximab with azathioprine, adalimumab with azathioprine, and golimumab with azathioprine were reviewed. Table 1 displays the total FAERS reports of ADRs and reported HZ infection in patients treated for UC. The JAK inhibitor tofacitinib showed increased risk of HZ with 58 total reports (ROR 2.79). In addition, methotrexate (ROR 1.83), azathioprine (ROR 1.74), 6-mercaptopurine (ROR 2.4), infliximab (ROR 2.49), and combination therapies of infliximab with methotrexate (ROR 2.61) and infliximab with azathioprine (ROR 2.91) demonstrated increased risk."

Adverse events • Review • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster • ROR1

Risk of Herpes Zoster in Patients With Inflammatory Bowel Disease Treated With Janus Kinase Inhibitors Compared With Anti-TNF Therapy: A Retrospective Cohort Study (ACG 2026) - "2 Advanced therapy was defined infliximab, adalimumab, certolizumab pegol, golimumab, vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, etrasimod, ozanimod, guselkumab, and mirikizumab. Among 8,293 patients with IBD, 3,164 received JAKi and 5,129 received anti-TNF therapy (Table 1). JAKi-treated patients had higher HZ incidence rates than anti-TNF patients (32.81 vs. 14.58 per 1,000 person-years; p< 0.001)."

Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

Risk of Incident Inflammatory Bowel Disease Among Patients With Psoriasis Treated With IL-17 Versus TNF Inhibitors: A Propensity-Matched TriNetX Study (ACG 2026) - "Adults (â¥18 years) with psoriasis initiating an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab, or bimekizumab) were compared with those starting a TNF inhibitor (adalimumab, infliximab, golimumab, or certolizumab pegol) after diagnosis...Cohorts underwent 1:1 propensity score matching on age, sex, race, ethnicity, diabetes, obesity, celiac disease, tobacco use, psoriatic arthritis (a disease-severity marker), and NSAID, antimicrobial, glucocorticoid, and methotrexate use, yielding 20,547 patients per cohort... After excluding prior IBD, 20,368 IL-17 and 18,987 TNF inhibitor users remained. At 1 year, incident IBD occurred in 46 IL-17 versus 79 TNF users (0.2% vs 0.4%), with significantly lower risk for IL-17 (relative risk [RR] 0.54, 95% CI 0.38â0.78; hazard ratio [HR] 0.56, 95% CI 0.39â0.81; log-rank p=0.002). At 3 years, IBD occurred in 85 versus 161 patients (0.4% vs 0.8%; RR 0.49, 95% CI 0.38â0.64; HR 0.54, 95% CI 0.42â0.70;..."

Clinical • Celiac Disease • Crohn's disease • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nicotine Addiction • Obesity • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A

Collateral Damage: IgA Nephropathy Complicating Long-Term Certolizumab Pegol Use in Crohn's Disease (ACG 2026) - "Case Description/ A 36-year-old male with CD diagnosed in 2010 (Paris classification: A2, L1, B2), underwent ileocolonic resection and was started on certolizumab pegol in 2011 after failing 5-aminosalicylic acid, 6-mercaptopurine, and infliximab therapy...Certolizumab pegol was stopped and CD treatment with vedolizumab was started. Treatment with corticosteroids, mycophenolate, losartan, and atrasentan was initiated...Targeted budesonide was not a treatment option in this case given prior bowel resection, which emphasizes a treatment consideration unique to CD patients. This case emphasizes the importance of routine renal monitoring in patients on long-term anti-TNF therapy. Figure: Light microscopy (PAS stain) demonstrating mesangial hypercellularity Figure: Immunofluorescence microscopy demonstrating diffuse mesangial IgA deposits"

Crohn's disease • Gastroenterology • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammation • Inflammatory Bowel Disease • Nephrology • Renal Disease

Dual Biologic Therapy in a Pregnant Patient With Crohn's Disease and Axial Spondyloarthritis (ACG 2026) - "She had previous non-response to mesalamine, mercaptopurine, certolizumab pegol, adalimumab, infliximab, and upadacitinib, as well as combination therapy with upadacitinib and vedolizumab. She then achieved clinical remission with a combination of risankizumab and golimumab...Recent randomized trials showed improved rates of clinical remission in patients with ulcerative colitis and Crohnâs disease treated with dual therapy with guselkumab and golimumab compared to monotherapy...Data from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes (PIANO) registry has shown no increased risk of pregnancy complications in patients treated with anti-TNF medications, immunomodulators, TNF/immunomodulator combination therapy, vedolizumab, and ustekinumab in patients with IBD. This case highlights emerging therapeutic strategies and the importance of patient centered multidisciplinary care for optimal pregnancy outcomes."

Clinical • Ankylosing Spondylitis • Axial Spondyloarthritis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis • CRP

Renal Involvement in Crohnâs Disease: An Uncommon Extraintestinal Manifestation (ACG 2026) - "Psoriatic arthritis was initially managed with adalimumab which likely masked his underlying CD until formal diagnosis in 2018 after which he was transitioned to certolizumab...He was treated with pulse-dose and taper of corticosteroids with continuation of risankizumab...Figure: Interstitial inflammation, tubulitis, and an epithelioid granuloma. (Masson trichrome stain, 20x objective)"

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Nephrology • Psoriasis • Psoriatic Arthritis • Renal Calculi • Renal Disease • Sarcoidosis • Seronegative Spondyloarthropathies • TNFA

Upadacitinib for Fistulizing Perianal Crohnâs Disease and Comorbid Enteropathic Arthritis Refractory to Combination Therapy (ACG 2026) - "In addition to tumor necrosis factor-alpha inhibitors (anti-TNF), the 2025 ACG Clinical Guideline on CD now suggests upadacitinib, ustekinumab, and vedolizumab for induction of remission of FPCD: conditional recommendation - very low level of evidence...The patient failed infliximab and adalimumab therapy before developing small bowel obstructions and an abscess...Adalimumab dosing was escalated but he was ultimately switched to certolizumab pegol-azathioprine combination therapy...Figure: Figure 1: Axial contrast-enhanced CT of the pelvis demonstrating chronic left perianal fistulizing Crohn's disease with a fistulous tract extending toward the medial gluteal fold and a curvilinear seton in situ, with surrounding inflammatory soft-tissue changes. Figure: Figure 2: Timeline of immunomodulatory therapy, corticosteroid exposure, and C-reactive protein levels during the patient's clinical course, illustrating improvement in perianal disease and inflammatory..."

Combination therapy • Crohn's disease • Gastroenterology • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Rheumatology • CRP

Arabic Translation and Validation of the IBD-Control Questionnaire in Patients With Inflammatory Bowel Disease (ACG 2026) - "Figure: IQR, interquartile range; CD, Crohnâs disease; UC, ulcerative colitis; HBI, Harvey-Bradshaw Index; CRP, C-reactive protein; FCP, fecal calprotectin; AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; IFX, infliximab; VDZ, vedolizumab; UST, ustekinumab; RZB, risankizumab; TOFA, tofacitinib; UPA, upadacitinib; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale; FACIT-F, Functional Assessment of Chronic Illness TherapyâFatigue; VAS, visual analogue scale. A total of 203 patients completed the Arabic IBD-CQ (median age 31, 40.9% female, 70.0% CD) (Table 1) completed the Arabic IBD-CQ. The Arabic IBD-CQ demonstrated excellent internal consistency (Cronbach's α=0.820); all 8 items had corrected item-total râ¥0.44, and no item improved α if deleted. Construct validity was strong with expected-direction correlations: FACIT-F Ï=+0.61, HADS-Anxiety Ï=â0.53,..."

Clinical • CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Ulcerative Colitis • CRP

Prevalence and Predictors of Fatigue in Inflammatory Bowel Disease: A Cross-Sectional Cohort Study With Subgroup Analysis of Quiescent Disease (ACG 2026) - "AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; HBI, Harvey-Bradshaw Index; IFX, infliximab; PSQI, Pittsburgh Sleep Quality Index; RZB, risankizumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VDZ, vedolizumab. A total of 215 patients (71.2% Crohnâs, 42.3% female, median age 30) completed FACIT-F; 201 (93.5%) had classifiable IBD clinical activity (69 active, 132 quiescent) and included in the analysis. Moderate-severe fatigue affected 82 (38.1%) overall; 44.9% in active and 33.3% in quiescent disease (50% in those with elevated biomarkers) (Figure 1A). On univariate analysis, moderate-severe fatigue was associated with HBI (p=0.034), CRP (p=0.03), poor sleep (PSQIâ¥5; p< 0.001), depression (HADS-D â¥8; p< 0.001) and anxiety (HADS-A â¥8; p< 0.001) (Table 1)."

CNS Disorders • Crohn's disease • Depression • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • CRP

Prevalence and Predictors of Poor Sleep Quality in Inflammatory Bowel Disease: A Cross-Sectional Cohort Study (ACG 2026) - "AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; HBI, Harvey-Bradshaw Index; IFX, infliximab; PSQI, Pittsburgh Sleep Quality Index; RZB, risankizumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VDZ, vedolizumab. A total of 215 patients (71.2% Crohnâs, 42.3% female, median age 30) completed the PSQI. Of these patients, 201 (93.5%) had classifiable IBD activity (69 Active, 132 Quiescent) and were included in the analysis. Poor sleep was noted in 62.3%, depression (HADS-D ⥠8) in 30.7% and anxiety (HADS-A ⥠8) in 35.2% of the entire cohort."

CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Sleep Disorder

Age-Dependent Effects of GLP-1 Receptor Agonists on Clinical Outcomes in Inflammatory Bowel Disease: A Propensity-Matched Real-World Study (ACG 2026) - "Within each, GLP-1 RA users were propensity score matched 1:1 to non-users on gender; race/ethnicity (Hispanic, White, African-American, Asian, other); type 2 diabetes; Crohnâs disease; ulcerative colitis; hyperlipidemia; hypertension; ischemic heart disease; CKD; MASLD; obesity; insulin; SGLT2 inhibitors; prior hospitalization; and baseline IBD therapy including aminosalicylates (mesalamine, sulfasalazine), thiopurines/immunomodulators (azathioprine, mercaptopurine, methotrexate), anti-TNF agents (infliximab, adalimumab, certolizumab pegol, golimumab), vedolizumab, IL-12/23 and IL-23 inhibitors (ustekinumab, risankizumab), and JAK inhibitors (tofacitinib, upadacitinib). Primary cohorts (vs non-users): 1,958 (18â45), 5,412 (45â65), 2,928 ( >65). GLP-1 RA use was associated with lower hospitalization, ED visits, and IV corticosteroid use across all cohorts (Table 1, Figure 1). The 45â65 cohort had the most comprehensive benefit: reduced all-cause..."

Clinical • Clinical data • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Crohn's disease • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Pancreatitis • Renal Disease • Type 2 Diabetes Mellitus • Ulcerative Colitis • IL12A • IL23A

Safety of Inadvertent Live Vaccine Administration in Patients With Inflammatory Bowel Disease on Immune-Modifying Therapy (ACG 2026) - "The exposed cohort comprised IBD patients who received a live vaccine (measles, mumps, and rubella (MMR), varicella, measles, mumps, rubella, and varicella (MMRV)...Inclusion required a vaccine CPT code, â¥12 months of continuous enrollment prior to index date, an IBD diagnosis (â¥2 IBD-related outpatient visits), and a prescription for an immune-modifying therapy (anti-tumor necrosis factor (TNF), vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, guselkumab, or mirikizumab) < 90 days of the index date...³Anti-TNF agents: infliximab, adalimumab, certolizumab, golimumab...6Immunomodulators: methotrexate, azathioprine, 6-mercaptopurine... 220 IBD patients met inclusion criteria for the live vaccine cohort (132 MMR, 73 varicella, 15 MMRV); 170 (77%) were on anti-TNF therapy and 30 (14%) on vedolizumab (Figure). The comparator group comprised 2,204 PCV13 recipients Table for baseline demographics. All-cause hospitalization or ED..."

Clinical • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Pneumococcal Infections • Rubella • Varicella Zoster • IL23A

Real-World Effectiveness of Anti-IL-23 vs Anti-TNF Monoclonal Antibodies in IBD: A Propensity Score-Weighted Analysis (ACG 2026) - "RIS = Risankizumab, GUS = guselkumab, UST = ustekinumab, CTZ = certolizumab, ADA = adalimumab, GOL = golimumab, IFX = infliximab and -BS = biosimilar. In 137 patients with UC and 260 with CD, there were significant baseline differences between the IL23A and TNFA groups (Fig 1). Over 90% of the estimated sample size in each cohort was retained after fitting propensity score weighted models. In patients with UC, IL23A was associated with increased odds of clinical response at all 3 timepoints and remission (notably post-induction, OR 1.93, p < 0.05) (Fig 2a)."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review. (PubMed, Dermatol Ther (Heidelb)) - "Topical clindamycin, benzoyl peroxide, chlorhexidine, and selected beta-lactam antibiotics appear to represent preferred options for mild disease or acute flares, whereas tetracyclines, retinoids, spironolactone, apremilast, Janus kinase inhibitors, and most glucagon-like peptide-1 (GLP-1) receptor agonists require avoidance or discontinuation because of fetal or neonatal safety concerns. Among biologics, tumor necrosis factor-α inhibitors remain the best-characterized agents, with certolizumab pegol offering minimal placental transfer and adalimumab or infliximab requiring individualized decisions regarding continuation and timing of discontinuation. Evidence for newer agents, including secukinumab and bimekizumab, is evolving but remains more limited. The review also highlights the importance of preconception counseling, medication transition, multidisciplinary delivery planning, postpartum flare prevention, breastfeeding-compatible therapy, and individualized..."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Oncology • Women's Health

Real-World Cardiovascular and Mortality Outcomes of Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis (ACR Convergence 2026) - "TNF inhibitors comprised adalimumab, etanercept, infliximab, certolizumab pegol, and golimumab. JAK inhibitors included tofacitinib, baricitinib, and upadacitinib... In this real-world study, Janus kinase inhibitors were associated with higher long-term mortality and a modest increase in major adverse cardiovascular events compared with tumor necrosis factor inhibitors, with notable differences across individual agents. These findings highlight the need for careful cardiovascular and thrombotic risk assessment when selecting JAK inhibitor therapy and support further prospective studies to refine patient selection."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Venous Thromboembolism

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "This review has supported evidence generation, but head-to-head comparative trials for key interventional subclasses or specific agents may be needed, as guided by key stakeholders; for example, on the use of biosimilar versions of medications out of patent. The role of concomitant purine analogues is a key confounding factor and future studies may not only want to investigate specifically the role of combinations, but also consider stratifying populations or purposefully excluding participants based on this key class of therapy to avoid such heterogeneity. Given the majority of evidence focusses on the outcomes of clinical remission and relapse, future studies may want to further consider other outcomes of clear interest to clinicians and patients, particularly endoscopic remission. Finally, long-term safety data are limited throughout the networks. Whilst future studies with longer follow-ups could provide increased data, it may be that study designs outside of..."

Clinical • Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IL7R

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "We found high-certainty evidence that nine therapies and moderate-certainty evidence that two therapies provide a clinically important benefit in improving disease activity compared to placebo for people with rheumatoid arthritis after failure of b/ts DMARD therapy. There was significant uncertainty surrounding treatment-related harms, with the evidence having been downgraded for serious or extremely serious imprecision. Pair-wise comparisons showed no significant differences among therapies, although the certainty of evidence was low. The lack of clarity regarding safety and comparative efficacy suggests that treatment decisions should be guided by individual patient characteristics and preferences."

Clinical • Journal • Retrospective data • Review • Fatigue • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Pain • Rheumatoid Arthritis • Rheumatology • IL6

Effectiveness and retention of certolizumab pegol and JAK inhibitors in rheumatoid arthritis: a multicenter retrospective study stratified by rheumatoid factor status. (PubMed, Front Med (Lausanne)) - "This multicentre retrospective cohort included RA patients initiating CZP or JAKi (baricitinib, filgotinib, tofacitinib, upadacitinib) between 2010 and 2024. A numerical difference in treatment retention favouring CZP was also observed. These findings highlight the potential importance of considering RF levels when selecting treatment and warrant further investigation in prospective studies."

Journal • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Risk of Malignant Melanoma with biologic- or targeted synthetic disease-modifying therapies in patients with rheumatoid arthritis: a Swedish Nationwide Cohort Study (EULAR 2026) - "Exposures were categorized as (i) JAKi (baricitinib, filgotinib, upadacitinib, tofacitinib), (ii) non-TNFi (abatacept, rituximab, sarilumab, tocilizumab), and (iii) TNFi (adalimumab, certolizumab, etanercept, golimumab, infliximab). However, for both drug classes there were signals of an internal shift in the distribution of invasive (approximately 1 extra annual case for every 2000 patients) vs. in situ MM (approximately 1 fewer annual case for every 2000 patients). Abatacept was associated with an increased risk of MM overall."

Clinical • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Immune Modulation • Immunology • Infectious Disease • Inflammatory Arthritis • Melanoma • Metabolic Disorders • Nephrology • Non-melanoma Skin Cancer • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Skin Cancer • Solid Organ Transplantation • Solid Tumor